🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  2. RITUXIMAB , DOXORUBICIN , VINCRISTINE , IBRUTINIB , RITUXIMAB, PREDNISONE , CYCLOPHOSPHAMIDE

    Fondazione Telethon ETS

    Diffuse Large B-cell Lymphoma ABC

    phase 2 small molecule active

    1 trial

  3. Radiotherapy

    The First People's Hospital of Lianyungang

    Cholangiocarcinoma

    phase 2 other terminated

    1 trial

  4. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  5. Recombinant COVID-19 Vaccine (CHO cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  6. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 2 mab active

    1 trial

  7. Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-09)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 2 mab active

    1 trial

  8. Recombinant Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure With Hemodialysis

    phase 2 small molecule active

    1 trial

  9. Recovery by Choice

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  10. Retinol

    Aspire Biopharma Holdings

    Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  11. SIRT Yttrium-90

    Chinese University of Hong Kong

    Cholangio Carcinoma

    phase 2 small molecule completed

    1 trial

  12. SYNTOCINON 40 i.e./ml pršilo za nos, raztopina, Oxytocin Placebo

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial

  13. Softisan 378, Cannabidiol

    Disc Medicine

    psychological disorders: PTSD; Anxiety disorders

    phase 2 small molecule active

    1 trial

  14. Standard of care and PrEP Choice at Enrollment

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other active

    1 trial

  15. Sublingual film containing Dexmedetomidine

    BioXcel Therapeutics

    Agitation,Psychomotor

    phase 2 small molecule completed

    1 trial

  16. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  17. TREMELIMUMAB, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., CISPLATINO Pfizer 50 mg/50 ml soluzione per infusione, DURVALUMAB

    Fondazione Telethon ETS

    locally advanced cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  18. TYRA-300 0.125 mg/kg

    Tyra Biosciences

    Achondroplasia

    phase 2 small molecule active

    1 trial

  19. Terbinafin "Moberg Pharma", kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terclara, kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea

    Lacuna Pharma Pty Ltd

    Distal Subungual Onychomycosis

    phase 2 small molecule active

    1 trial

  20. TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  21. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  22. TransCon hGH, TransCon hGH, TransCon CNP

    Lacuna Pharma Pty Ltd

    Children with Achondroplasia

    phase 2 small molecule active

    1 trial

  23. Trichostatin A

    Vanda Pharmaceuticals Netherlands B.V.

    Onychomycosis of Toenail

    phase 2 small molecule active

    1 trial

  24. URSODEOXYCHOLIC ACID

    The George Institute

    Hepatorenal polycystic diseases

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources